mouse anti human c5b c9 neo ae11 alexafluor594 Search Results


mouse anti human c5b c9 neo ae11 alexafluor594  (Novus Biologicals)
93
Novus Biologicals mouse anti human c5b c9 neo ae11 alexafluor594
Complement component deposition on the surface of different cell lines after application of the monoclonal AQP4 antibody E5415A (10 µg/mL) and active or heat-inactivated human complement. ( A ) Terminal complement complex (TCC) formation on U-87MG-AQP4-ECFP cells. After the treatments, cells were washed with PBS with 10% heat-inactivated FCS, and mouse anti-human <t>C5b-C9</t> neo <t>(aE11)</t> <t>AlexaFluor594</t> (Novus Biologicals) was applied with 5 µg/mL to visualize TCC deposition on the cell surface. ( B–D ) Complement component C3/C3b/iC3b deposition. After the treatments, cells were washed with PBS with 10% heat-inactivated FCS, and mouse anti-human/mouse C3/C3b/iC3b purified (6C9) (Cedarlane) was applied with 5 µg/mL, followed by 2 µg/mL goat-anti mouse IgG1 Cross-Adsorbed Secondary Antibody, AlexaFluor594 (Invitrogen, Thermo Fisher Scientific) to visualize opsonization by C3/C3b/iC3b on the cell surface of ( B ) U-87MG-AQP4-ECFP cells, ( C ) U-87MG-ECFP cells and ( D ) primary human astrocytes. Scale bar = 20 μm. AF , Alexa Fluor; AQP4, aquaporin-4; DAPI, 4′,6-diamidino-2-phenylindole; ECFP, enhanced cyan fluorescent protein.
Mouse Anti Human C5b C9 Neo Ae11 Alexafluor594, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti human c5b c9 neo ae11 alexafluor594/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
mouse anti human c5b c9 neo ae11 alexafluor594 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

Image Search Results


Complement component deposition on the surface of different cell lines after application of the monoclonal AQP4 antibody E5415A (10 µg/mL) and active or heat-inactivated human complement. ( A ) Terminal complement complex (TCC) formation on U-87MG-AQP4-ECFP cells. After the treatments, cells were washed with PBS with 10% heat-inactivated FCS, and mouse anti-human C5b-C9 neo (aE11) AlexaFluor594 (Novus Biologicals) was applied with 5 µg/mL to visualize TCC deposition on the cell surface. ( B–D ) Complement component C3/C3b/iC3b deposition. After the treatments, cells were washed with PBS with 10% heat-inactivated FCS, and mouse anti-human/mouse C3/C3b/iC3b purified (6C9) (Cedarlane) was applied with 5 µg/mL, followed by 2 µg/mL goat-anti mouse IgG1 Cross-Adsorbed Secondary Antibody, AlexaFluor594 (Invitrogen, Thermo Fisher Scientific) to visualize opsonization by C3/C3b/iC3b on the cell surface of ( B ) U-87MG-AQP4-ECFP cells, ( C ) U-87MG-ECFP cells and ( D ) primary human astrocytes. Scale bar = 20 μm. AF , Alexa Fluor; AQP4, aquaporin-4; DAPI, 4′,6-diamidino-2-phenylindole; ECFP, enhanced cyan fluorescent protein.

Journal: Scientific Reports

Article Title: Inflammatory transcriptomic signatures in a human cellular NMOSD model reveal upregulation of NF-κB and IL6 pathways

doi: 10.1038/s41598-025-27335-9

Figure Lengend Snippet: Complement component deposition on the surface of different cell lines after application of the monoclonal AQP4 antibody E5415A (10 µg/mL) and active or heat-inactivated human complement. ( A ) Terminal complement complex (TCC) formation on U-87MG-AQP4-ECFP cells. After the treatments, cells were washed with PBS with 10% heat-inactivated FCS, and mouse anti-human C5b-C9 neo (aE11) AlexaFluor594 (Novus Biologicals) was applied with 5 µg/mL to visualize TCC deposition on the cell surface. ( B–D ) Complement component C3/C3b/iC3b deposition. After the treatments, cells were washed with PBS with 10% heat-inactivated FCS, and mouse anti-human/mouse C3/C3b/iC3b purified (6C9) (Cedarlane) was applied with 5 µg/mL, followed by 2 µg/mL goat-anti mouse IgG1 Cross-Adsorbed Secondary Antibody, AlexaFluor594 (Invitrogen, Thermo Fisher Scientific) to visualize opsonization by C3/C3b/iC3b on the cell surface of ( B ) U-87MG-AQP4-ECFP cells, ( C ) U-87MG-ECFP cells and ( D ) primary human astrocytes. Scale bar = 20 μm. AF , Alexa Fluor; AQP4, aquaporin-4; DAPI, 4′,6-diamidino-2-phenylindole; ECFP, enhanced cyan fluorescent protein.

Article Snippet: After the treatments, cells were washed with PBS with 10% heat-inactivated FCS, and mouse anti-human C5b-C9 neo (aE11) AlexaFluor594 (Novus Biologicals) was applied with 5 μg/mL to visualize TCC deposition on the cell surface. ( B–D ) Complement component C3/C3b/iC3b deposition.

Techniques: Purification

Immunocytochemistry of U-87MG-AQP4-ECFP cells after treatment with NMOSD patient sera and human complement. U-87MG-AQP4-ECFP cells were treated with 10% NMOSD patient sera (with or without AQP4-IgG) in combination with active or heat-inactivated human complement. Then, the cells were washed with PBS with 10% heat-inactivated fetal calf serum, and immunocytochemistry was performed. ( A ) Terminal complement complex (TCC) staining. The cellular surface was stained for TCC deposition by applying mouse anti-C5b-C9 neo (aE11) AlexaFluor594 (Novus Biologicals) with 5 µg/mL. ( B ) NF-κB component p65 staining. Translocation of p65 from the cytosol into the nucleus was visualized by intracellular immunocytochemistry. Cells were fixed, permeabilized, and blocked. Then, 2 µg/mL rabbit anti-human p65 (D14E12) (Cell Signaling) served as the primary antibody, followed by goat anti-rabbit AlexaFluor647 (Invitrogen, Thermo Fisher Scientific). White arrows indicate p65 translocation into the nucleus. Scale bar = 20 μm. AF, Alexa Fluor; DAPI, 4′,6-diamidino-2-phenylindole; TCC, terminal complement complex.

Journal: Scientific Reports

Article Title: Inflammatory transcriptomic signatures in a human cellular NMOSD model reveal upregulation of NF-κB and IL6 pathways

doi: 10.1038/s41598-025-27335-9

Figure Lengend Snippet: Immunocytochemistry of U-87MG-AQP4-ECFP cells after treatment with NMOSD patient sera and human complement. U-87MG-AQP4-ECFP cells were treated with 10% NMOSD patient sera (with or without AQP4-IgG) in combination with active or heat-inactivated human complement. Then, the cells were washed with PBS with 10% heat-inactivated fetal calf serum, and immunocytochemistry was performed. ( A ) Terminal complement complex (TCC) staining. The cellular surface was stained for TCC deposition by applying mouse anti-C5b-C9 neo (aE11) AlexaFluor594 (Novus Biologicals) with 5 µg/mL. ( B ) NF-κB component p65 staining. Translocation of p65 from the cytosol into the nucleus was visualized by intracellular immunocytochemistry. Cells were fixed, permeabilized, and blocked. Then, 2 µg/mL rabbit anti-human p65 (D14E12) (Cell Signaling) served as the primary antibody, followed by goat anti-rabbit AlexaFluor647 (Invitrogen, Thermo Fisher Scientific). White arrows indicate p65 translocation into the nucleus. Scale bar = 20 μm. AF, Alexa Fluor; DAPI, 4′,6-diamidino-2-phenylindole; TCC, terminal complement complex.

Article Snippet: After the treatments, cells were washed with PBS with 10% heat-inactivated FCS, and mouse anti-human C5b-C9 neo (aE11) AlexaFluor594 (Novus Biologicals) was applied with 5 μg/mL to visualize TCC deposition on the cell surface. ( B–D ) Complement component C3/C3b/iC3b deposition.

Techniques: Immunocytochemistry, Staining, Translocation Assay